Norges Bank Terns Pharmaceuticals, Inc. Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$3.37 - $6.86 $1.44 Million - $2.93 Million	426,700 New	426,700 $2.77 Million
Q3 2023 Nov 13, 2024	BUY	$4.7 - $8.55 $2.01 Million - $3.65 Million	426,700 New	426,700 $2.15 Million
Q2 2023 Aug 14, 2024	BUY	$7.35 - $13.29 $1.2 Million - $2.18 Million	163,900 New	163,900 $1.43 Million
Q2 2021 Aug 10, 2021	SELL	$12.26 - $22.0 $282,813 - $507,496	-23,068 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$17.13 - $27.25 $395,154 - $628,603	23,068 New	23,068 $507,000

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $214M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.